Le Lézard
Classified in: Health
Subjects: RCL, CFG

Advisory - One lot of Pharmasave Advanced Relief Eye Drops and Compliments Advanced Relief Eye Drops recalled because of a packaging error that may pose health risks


OTTAWA, ON, May 7, 2022 /CNW/ -

Summary
Issue

Teva Canada Ltd. is recalling one lot each of Pharmasave Advanced Relief Eye Drops and Compliments Advanced Relief Eye Drops because of a packaging error. Some bottles may contain ingredients that are not listed on the label and that may pose health risks to individuals who are allergic to the ingredients.

The products are used for the temporary relief of eye redness due to minor eye irritation, burning and dryness. They are labelled for use by adults and children 6 years of age and older.

Following a complaint involving the Pharmasave eye drops, the company identified that some bottles in one lot of both the Pharmasave and Compliments products may have been packaged with another eye-drop product that contains different active ingredients. Glycerine 0.25% and naphazoline HCl 0.012% were present in bottles which were labelled to contain Dextran 70 0.1%, Povidone 1%, Polyethylene glycol 400 1%, Tetrahydrozoline hydrochloride 0.05%.  

Naphazoline HCl or glycerine may cause a reaction in individuals allergic to these ingredients. Signs of an allergic reaction include rash, and itching or swelling, especially of the face, tongue and throat.

Cartons of the affected Pharmasave and Compliments eye drops are labelled with lot number AR21C03. The affected bottles may be labelled with either lot number AR21C03 or RL21D01.

Health Canada is monitoring the company's recall and implementation of any necessary corrective and preventative actions. If additional safety information is identified, Health Canada will take appropriate action and inform Canadians as needed.

Affected products

Product

DIN

Lot

Expiry

Pharmasave Advanced Relief Eye Drops, 15 mL

02344319

AR21C03 (on
cartons and
some bottles)

RL21D01 (on
some bottles)

31 Mar 2024

Compliments Advanced Relief Eye Drops, 15 mL

02344319

AR21C03 (on
cartons and
some bottles)


RL21D01 (on
some bottles)

31 Mar 2024

What you should do
Images

Pharmasave Advanced Relief Eye Drops, 15 mL (bottle)

Pharmasave Advanced Relief Eye Drops, 15 mL (bottle) (CNW Group/Health Canada)

Pharmasave Advanced Relief Eye Drops, 15 mL (carton)

Pharmasave Advanced Relief Eye Drops, 15 mL (carton) (CNW Group/Health Canada)

Compliments Advanced Relief Eye Drops, 15 mL (bottle)

Compliments Advanced Relief Eye Drops, 15 mL (bottle) (CNW Group/Health Canada)

Compliments Advanced Relief Eye Drops, 15 mL (carton)

Compliments Advanced Relief Eye Drops, 15 mL (carton) (CNW Group/Health Canada)

Également disponible en français

SOURCE Health Canada


These press releases may also interest you

at 06:03
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...

at 06:00
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...

at 05:30
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...



News published on and distributed by: